Common questions
Cagrilintide — questions, answered plainly.
5 research-context questions about Cagrilintide. Answers stay neutral and reference what is published in the peer-reviewed literature — no dosing, no human-use guidance, no extrapolation beyond what the cited studies report.
- 01
What is cagrilintide?
Cagrilintide (development code AM833) is an acylated long-acting analogue of the endogenous pancreatic hormone amylin. It is designed for once-weekly subcutaneous dosing. The compound is investigational — not yet FDA-approved at the time of writing.
- 02
What is amylin?
Amylin is an endogenous peptide hormone co-secreted with insulin by pancreatic β-cells. It contributes to glucose regulation through satiety signalling, delayed gastric emptying, and suppression of postprandial glucagon. Cagrilintide is designed as a long-acting analogue of this physiology.
- 03
What did the Phase 2 cagrilintide trial show?
Lau et al. 2021 (Lancet, PMID 34798060; n=706) reported dose-dependent mean weight reductions of 6.0%–10.8% with cagrilintide 0.3–4.5 mg weekly versus 3.0% with placebo over 26 weeks in adults with overweight/obesity.
- 04
What is CagriSema?
CagriSema is a combination of cagrilintide and semaglutide, developed for obesity. CagriSema clinical research is a separate programme; this profile covers cagrilintide monotherapy evidence. The D'Ascanio 2024 review (PMID 36883831) discusses the combination rationale.
- 05
What are the limits of the cagrilintide evidence?
Most primary cagrilintide data come from a single Phase 2 dose-finding RCT (Lau 2021, n=706). Phase III evidence is accumulating but not yet established at the time of writing. Clinical use is investigational.
Important
These answers are not medical advice.
Cagrilintide is referenced in research literature only. Palthera does not provide dosage, cycling, stacking, or injection guidance, and content is not intended to support consumer or therapeutic use. Speak to a qualified clinician for any health decisions.